Artikel: Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.
2020 Band 59, Heft 5, Seite(n) 102875
Abstract: Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been ...
| Abstract | Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy. |
|---|---|
| Mesh-Begriff(e) | Adult ; Aged ; Aged, 80 and over ; COVID-19/immunology ; COVID-19/therapy ; Female ; Humans ; Immunization, Passive/adverse effects ; Male ; Middle Aged ; SARS-CoV-2/immunology ; SARS-CoV-2/physiology ; Treatment Outcome ; Young Adult ; COVID-19 Serotherapy |
| Schlagwörter | covid19 |
| Sprache | Englisch |
| Erscheinungsdatum | 2020-07-15 |
| Erscheinungsland | England |
| Dokumenttyp | Clinical Trial ; Journal Article ; Multicenter Study |
| ZDB-ID | 2046795-3 |
| ISSN | 1878-1683 ; 1473-0502 |
| ISSN (online) | 1878-1683 |
| ISSN | 1473-0502 |
| DOI | 10.1016/j.transci.2020.102875 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 1739: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.